ReviewCureus2025
Scientific Publications on the Association Between Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Bibliometric Study From 2010 to 2024.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This bibliometric review analyzed global research trends on the relationship between obstructive sleep apnea hypopnea syndrome (OSAHS) and metabolic dysfunction-associated steatotic liver disease (MASLD) from 2010 to 2024. A total of 115 PubMed-indexed publications were identified using Medical Subject Headings (MeSH)-based search strategies, with citation counts and journal impact factors obtained from Web of Science. The analysis considered multiple bibliometric indicators, including publication counts, citation frequencies, author productivity, journal impact, country contributions, and publication languages. Over the study period, research output increased at a compound annual growth rate (CAGR) of 5.1%, peaking in 2021 with 13 publications. The average number of citations per year was 421.3, with a peak in 2013 (910 citations) and a citation CAGR of -23.9%, a pattern likely influenced by the shorter citation window of recent studies. Research activity was dominated by China and the United States, while no publications originated from Spanish-speaking countries despite the high regional prevalence of both conditions. These findings reveal a pronounced geographical imbalance in the literature, emphasizing the urgent need to stimulate research in underrepresented regions. Furthermore, the recent nomenclature transition from non-alcoholic fatty liver disease (NAFLD) to MASLD is expected to influence future bibliometric trends, requiring hybrid search strategies to ensure continuity in literature tracking during the transitional period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.